Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00262964
Status:
COMPLETED
Last Update Posted:
2018-07-11
First Post:
2005-12-06
Brief Title:
Obesity and Nonalcoholic Fatty Liver Disease
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Obesity and Nonalcoholic Fatty Liver Disease
Status:
COMPLETED
Status Verified Date:
2018-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary goal of this study is to provide a better understanding of 1 the pathogenesis and pathophysiology of non-alcoholic fatty liver disease NAFLD in obese subjects and 2 the effect of marked weight loss on the histologic and metabolic abnormalities associated with NAFLD The following hypotheses will be tested
1 obesity causes hepatic fat accumulation because of excessive fatty acid release from fat tissue and increased free fatty acid availability
2 increased hepatic liver fat content causes insulin-resistant glucose sugar production by the liver and altered liver protein synthesis
3 increased hepatic fat content causes increased lipid fat peroxidation hepatic inflammation necrosis and fibrosis and
4 marked weight loss improves NAFLD once patients are weight stable
1 obesity causes hepatic fat accumulation because of excessive fatty acid release from fat tissue and increased free fatty acid availability
2 increased hepatic liver fat content causes insulin-resistant glucose sugar production by the liver and altered liver protein synthesis
3 increased hepatic fat content causes increased lipid fat peroxidation hepatic inflammation necrosis and fibrosis and
4 marked weight loss improves NAFLD once patients are weight stable
Detailed Description:
Obesity is a major risk factor for non-alcoholic fatty liver disease NAFLD which represents a spectrum of liver diseases NAFLD is a major health problem in the US because of its high prevalence and causal relationship with serious liver abnormalities However the mechanismsresponsible for developing NAFLD in obese persons and the effects on liver function are not known This gap in knowledge has made it difficult to identify effective therapy The results from these studies will lay the groundwork for the development of novel therapeutic interventions for NAFLD in obese patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01DK037948 | NIH | None | httpsreporternihgovquickSearchR01DK037948 |